Use Of SB-705498 In The Acute Treatment Of Migraine
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Despite the success of the triptan class of drugs, approximately 60% of patients who take
medication at the moderate to severe pain stage of acute migraine, still have pain of mild or
greater degree at 2 hrs post dose. SB-705498 is a novel, first in class TRPV1 receptor
antagonist under development for the treatment of migraine pain. Preclinical experiments have
demonstrated that the TRPV1 receptor is expressed both centrally and peripherally in the
trigeminal system and inhibition of TRPV1 with SB-705498 can both prevent and reverse
established central sensitisation.